Changes in P2Y Purinergic Receptor Expression in the Ciliary Body in a Murine Model of Glaucoma

Frontiers in Pharmacology
Begoña FonsecaJesús Pintor

Abstract

Glaucoma is a neuropathology, often accompanied by an elevated intraocular pressure (IOP), which can lead to blindness. Since DBA/2J mice develop glaucoma, several studies of the physiopathology of glaucoma have been reported in this animal model. It is also known that purinergic receptors are involved in the pathology of glaucoma by controlling aqueous humor production and drainage and therefore controlling IOP. There are no studies on purinergic receptors in the DBA/2J model of glaucoma and their relation to the development of the pathology, so the aim of this study was to make an approach to the purinergic mechanisms involved in glaucoma. All the experiments were performed using DBA/2J and C57BL/6J mice and investigating P2Y1, P2Y2, and P2Y6 receptors. IOP measurements were made with a non-invasive rebound tonometer, and animals were instilled with diadenosine tetraphosphate (Ap4A) and the corresponding purinergic antagonists in order to see their effects on IOP. The expression of mRNA for P2Y1, P2Y2, and P2Y6 purinergic receptors was carried out by quantitative real-time PCR. Additionally, P2Y-receptor expression was performed by immunohistochemical techniques carried out on the ciliary processes. The results showed that IO...Continue Reading

References

May 1, 1996·British Journal of Pharmacology·J B SchachterT K Harden
Jun 17, 1998·Proceedings of the National Academy of Sciences of the United States of America·C H MitchellM M Civan
May 24, 2000·British Journal of Anaesthesia·G Burnstock
Mar 7, 2001·Nature Medicine·S I Tomarev
Nov 17, 2001·European Journal of Pharmacology·K PatelF Marshall
Dec 18, 2001·Nature Genetics·Michael G AndersonSimon W M John
Dec 26, 2001·The Journal of Pharmacology and Experimental Therapeutics·J PintorB Yerxa
Dec 20, 2002·The Journal of Pharmacology and Experimental Therapeutics·Jesús PintorCharles H V Hoyle
Jan 27, 2004·Molecular Pharmacology·Gary L Waldo, T Kendall Harden
Jun 11, 2005·The Journal of Pharmacology and Experimental Therapeutics·David SotoXavier Gasull
Oct 13, 2007·Progress in Retinal and Eye Research·Ana Guzmán-AranguezJesus Pintor
Nov 23, 2007·European Journal of Pharmacology·Anna MarkovskayaJesús Pintor
Apr 12, 2008·Purinergic Signalling·Jesús PintorAssumpta Peral
Jun 20, 2008·Pharmacology & Therapeutics·Almudena CrookeJesús Pintor
Dec 18, 2010·Experimental Eye Research·Ana Guzman-AranguezJesus Pintor
Jul 12, 2011·British Journal of Pharmacology·Alba Martin-GilJesus Pintor
Mar 19, 2013·The Journal of Pharmacology and Experimental Therapeutics·Ana Guzman-AranguezJesús Pintor
May 17, 2013·JAMA : the Journal of the American Medical Association·Hussein HollandsSanjay Sharma
Mar 19, 2014·Experimental Eye Research·María J Pérez de LaraJesús Pintor
Nov 17, 2016·Purinergic Signalling·Begoña FonsecaJesús Pintor

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Methods Mentioned

BETA
glycosylation
PCR

Software Mentioned

GraphPad
GraphPad Prism

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

The Journal of Pharmacology and Experimental Therapeutics
David SotoXavier Gasull
Investigative Ophthalmology & Visual Science
Wan-Heng WangAbbot F Clark
Acta Ophthalmologica Scandinavica
Leon N DaviesJames S Wolffsohn
© 2022 Meta ULC. All rights reserved